… The population of interest were individuals diagnosed with atypical hemolytic uremic syndrome.
Studies focusing exclusively on pregnancy-associated aHUS (p-aHUS) were excluded. …

… Our understanding and management of atypical hemolytic uremic syndrome (aHUS) have
dramatically improved in the last decade. aHUS has been established as a prototypic disease …

… Shiga toxin-associated hemolytic uremic syndrome and atypical hemolytic uremic
syndrome constitute the most common presentations in children and adults respectively. …

… Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy
(TMA), characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, …

Background: Atypical hemolytic uremic syndrome (aHUS) is an extremely rare, heterogeneous
disease of uncontrolled activation of the alternative complement pathway that is difficult to …

Atypical hemolytic-uremic syndrome (aHUS) is a life-threatening disease that in most cases
progresses to end-stage kidney disease. 1 Rare pathogenic mutations in complement …

… of atypical hemolytic uremic syndrome. We have conducted a systematic review on the
aHUS biomarkers: C3, C5a, C5b-9, factor B, complement factor B, H, and I, CH50, AH50, d-dimer, …

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia,
and renal failure caused by platelet thrombi in the microcirculation of the kidney and other …

… , despite recent advances in understanding the mechanisms of several types of TMA syndrome.
Atypical hemolytic uremic syndrome (aHUS) is caused by a genetic or acquired defect in …

… The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter open…